NewCardio Signs MSA With US CRO For QTinno
In addition, NewCardio has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, in order to accelerate its readiness
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.